title: Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
abstract: We aimed to assess the role of XPG, XPC and MMS19L polymorphisms on response to chemotherapy in osteosarcomas, and the clinical outcomes. One hundred and eighty five osteosarcoma patients who were histologically confirmed were enrolled in our study between January 2007 and December 2009. Genotyping of XPG, XPC and MMS19L was performed in a 384-well plate format on the MassARRAY® platform. Individuals with XPG TT genotype and T allele were more likely to be better response to chemotherapy than CC genotype, with the OR (95% CI) of 4.17 (1.64-11.54) and 2.66 (1.39-5.11), respectively. Those carrying MMS19L TT genotype and T allele showed better response to chemotherapy, with ORs (95% CI) of 4.8 (1.56-17.7) and 2.3 (1.22-4.36), respectively. Patients carrying TT genotype of XPG and MMS19L showed a significantly longer overall survival than CC genotype, with a 0.47 and 0.30-fold risk of death when compared with the wild-type of the gene. XPG and MMS19L are correlated with response to chemotherapy and prognosis of osteosarcoma, so that they could be used as predictive markers for prognosis.
authors.affiliation: Department of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, Changsha, China. baisb_777@126.com
authors.forename: Sheng-Bin
authors.initials: SB
authors.lastname: Bai
authors.forename: Hong-Xiang
authors.initials: HX
authors.lastname: Chen
authors.forename: Yong-Xing
authors.initials: YX
authors.lastname: Bao
authors.forename: Xuegang
authors.initials: X
authors.lastname: Luo
authors.forename: Jin-Jie
authors.initials: JJ
authors.lastname: Zhong
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D001859:Bone Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000556:secondary; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D004260:DNA Repair / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004317:Doxorubicin / Q000008:administration & dosage; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics*; D012516:Osteosarcoma / Q000188:drug therapy / Q000235:genetics / Q000401:mortality* / Q000473:pathology; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D014157:Transcription Factors / Q000235:genetics*; D055815:Young Adult; D000099250:DNA Excision Repair Protein ERCC-5
chemical_list: D014408:Biomarkers, Tumor; D002945:Cisplatin; D004268:DNA-Binding Proteins; D004317:Doxorubicin; D004720:Endonucleases; D008727:Methotrexate; D009687:Nuclear Proteins; D014157:Transcription Factors; D000099250:DNA Excision Repair Protein ERCC-5; C416322:MMS19 protein, human; C086984:XPC protein, human